Clinical Efficacy Of Wuguteng Tablets In The Adjuvant Treatment Of Refractory And Relapsed Acute Myeloid Leukemia And Myelodysplastic Syndrome Patients

Objective:To investigate the clinical efficacy of Wuguteng tablets in the adjuvant treatment of refractory and relapsed acute myeloid leukemia and Myelodysplastic Syndrom.Methods:There were40patients with refractory and relapsed acute myeloid leukemia and30patients with intermediate-1MDS which were divided into four groups respectively, including chemotherapy with Wuguteng tablets for2months., chemotherapy alone, supportive care with Wuguteng tablets for2months.and supportive care alone group. Traditional Chinese medicine symptom score, Eastern Cooperative Oncology Group (ECOG) score, complete blood count, blood transfusion interval, clinical efficacy of Wuguteng tablets were compared and analyzed among each group to evaluate the safety and efficacy of Wuguteng tablets in the adjuvant treatment of refractory and relapsed AML and MDS.Results:1. Patients with refractory and relapsed AML in chemotherapy with Wuguteng tablets group had higher efficacy than chemotherapy alone group, when Traditional Chinese medicine symptom score was emplpyed in evaluation. However, there was no statistical significance between the groups. After2month treatment, patients administered with chemotherapy and Wuguteng tablets had lower ECOG scores, elevated Hb and platelet value, lower white blood cell count and proloned red blood cell and platelet transfusion intervals. Among which, only platelet transfusion intervals and white blood cell counts had significant difference in patients completing2month treatment, with Wuguteng tablets. While in chemotherapy alone patients, there were no improvement in blood counts (P>0.05) and higher ECOG scores were recorded in this group of patients (P<0.05)2.Patients with intermediate-1MDS in supportive care plus Wuguteng group had higher efficacy than supportive care alone group evaluated with traditional Chinese medicine symptom score demonstrating no statistical significance. Improvement was recorded in supportive care plus Wuguteng group after2month treatment, including lower ECOG scores, higher Hb and platelet counts, prolonged transfusion intervals both with red blood cell and platelets (P<0.05). While in supportive care alone patients, no such improvement was found with significant difference (P>0.05) Conclusion:With the adjuvant treatment of Wuguteng tablets, patients with refractory and relapsed AML experienced prolonged average PLT transfusion intervals, possibly ameliorated Chinese clinical symptoms,lower white cell cout and elevated platelet count. While in patients with intermediate-1MDS, addition of Wuguteng tablets might improve both ECOG score and traditional Chinese clinical syptome scores elevate red blood cell and platelet counts and prolonge transfusion intervals.